RxDoctor Payments Data

Nitza Alvarez Torres, MD

Cardiovascular Disease · The Villages, FLNPI 1659491983

Payments from drug & device makers

$11,836in general payments, 2019–2025

Across 212 payments — averaging $55.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Boston Scientific$467
  • Abbott$403
  • Cvrx, Inc.$147
  • Edwards Lifesciences$117
  • Impulse Dynamics (USA) Inc.$104
  • plus $312 from 11 others

What the payments were for

  • Travel & lodging$5,74649%
  • Food & beverage$6,07651%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,836 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$2,210,405
Medicare patients
2,327
Services billed
18,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban962$1,305,993
XareltoRivaroxaban225$292,432
EntrestoSacubitril/Valsartan200$270,985
Repatha SureclickEvolocumab231$243,093
MultaqDronedarone Hcl43$82,783
JardianceEmpagliflozin64$74,260
BrilintaTicagrelor49$57,022
Repatha SyringeEvolocumab49$54,881
FarxigaDapagliflozin Propanediol46$46,891
CorlanorIvabradine Hcl45$42,870
Ranolazine ErRanolazine334$41,471
Praluent PenAlirocumab40$38,769
Flecainide Acetate379$20,793
LivaloPitavastatin Calcium32$20,452
EdarbiAzilsartan Medoxomil30$16,863

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$18$270,985200 claims
AstraZenecaBrilinta, Farxiga$44$103,91395 claims
AmgenCorlanor$75$42,87045 claims
Kowa Pharmaceuticals America, Inc.Livalo$30$20,45232 claims
Arbor Pharmaceuticals, Inc.Edarbi$12$16,86330 claims
Esperion Therapeutics, Inc.Nexletol$15$11,92113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →